Just to be clear TITAN does not own the IP to IREP. Columbia University does. Columbia and TITAN have a contractual agreement to the best of my knowledge to push this product through development (via Ximedica) to fruition as an ECM/FDA approved device. TITAN has not done well as we all know. There is probably so much going on behind the scenes that we have NO CLUE how bad things really are. I question how much longer Columbia is going to put up with management style? All the positive supposition here is just that.
I wish all the best and only hoped to see this thing succeed for my own financial objectives.....but as a long time investor these guys are FOS.
News 
Market Data 
Discover 
